Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
114 studies found for:    30607
Show Display Options
Rank Status Study
1 Active, not recruiting Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy
Conditions: Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Sunitinib Malate;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
2 Recruiting Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Copanlisib (BAY80-6946)
3 Recruiting A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Front-line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Ipatasertib;   Drug: Paclitaxel;   Drug: Placebo
4 Completed
Has Results
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
Conditions: Lung Cancer;   Chemotherapy-Induced Thrombocytopenia;   Non-Small Cell Lung Cancer;   Cancer;   Lung Neoplasms;   Oncology;   Solid Tumors;   Thrombocytopenia
Interventions: Biological: Romiplostim;   Drug: Placebo;   Drug: Gemcitabine;   Drug: Carboplatin;   Drug: Cisplatin
5 Completed
Has Results
Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
Condition: Metastatic Pancreatic Cancer
Interventions: Drug: Albumin-bound paclitaxel;   Drug: Gemcitabine
6 Completed Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)
Condition: Squamous Cell Lung Cancer
Interventions: Drug: gemcitabine/carboplatin;   Drug: gemcitabine/carboplatin plus Iniparib
7 Active, not recruiting Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer
Conditions: Prostate Cancer;   Castration Resistant Prostate Cancer;   Prostatic Neoplasms
Interventions: Drug: cabozantinib;   Drug: abiraterone;   Drug: prednisone
8 Unknown  Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Condition: Breast Cancer
Intervention: Drug: Bevacizumab (drug), Herceptin (drug)
9 Completed Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndrome (MDS)
Intervention: Drug: Ezatiostat Hydrochloride
10 Terminated
Has Results
Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: dexamethasone;   Drug: doxorubicin HCl liposome
11 Completed Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium
Conditions: Bladder Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urethral Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium
12 Completed Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer
Condition: Breast Cancer
Intervention: Drug: letrozole
13 Active, not recruiting S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: anastrozole;   Drug: fulvestrant
14 Completed Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer
Condition: Urinary Bladder Neoplasms
Interventions: Drug: larotaxel (XRP9881);   Drug: gemcitabine;   Drug: cisplatin
15 Active, not recruiting Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
Conditions: Colon Mucinous Adenocarcinoma;   Colon Signet Ring Cell Adenocarcinoma;   Lynch Syndrome;   Stage IIA Colon Cancer;   Stage IIB Colon Cancer;   Stage IIC Colon Cancer
Interventions: Drug: Oxaliplatin;   Drug: Leucovorin Calcium;   Drug: Fluorouracil;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis
16 Completed
Has Results
Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer
Conditions: Recurrent Small-cell Lung Cancer (SCLC);   Lung Cancer, Small Cell
Intervention: Drug: Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)
17 Recruiting A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Condition: Metastatic Breast Cancer HR+, HER2-
Interventions: Drug: Fulvestrant;   Drug: BKM120;   Drug: BKM120 matching placebo
18 Recruiting Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma
Condition: Melanoma
Interventions: Drug: LGX818;   Drug: LGX818+MEK162;   Drug: vemurafenib
19 Recruiting A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: LY2875358;   Drug: Erlotinib
20 Active, not recruiting A Study of Chemotherapy and Ramucirumab Versus (vs.) Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer Participants Who Received Prior First Line Platinum Based Chemotherapy
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Docetaxel;   Biological: Ramucirumab;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years